Knockdown of GALNT1 suppresses malignant phenotype of hepatocellular carcinoma by suppressing EGFR signaling

Oncotarget

Volumn 6, Issue 8, 2015, Pages 5650-5665

  Huang, Miao Juei ^a   Hu, Rey Heng ^b   Chou, Chih Hsing ^a   Hsu, Chia Lang ^c   Liu, Ya Wen ^a   Huang, John ^b   Hung, Ji Shiang ^b   Lai, I Rue ^a   Juan, Hsueh Fen ^c   Yu, Sung Liang ^a   Wu, Yao Ming ^b   Huang, Min Chuan ^a,c  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor; GalNAc transferase; GALNT1; O glycosylation; Receptor tyrosine kinase

Indexed keywords

EARLY ENDOSOME ANTIGEN 1; EPIDERMAL GROWTH FACTOR RECEPTOR; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MESSENGER RNA; N ACETYLGALACTOSAMINYLTRANSFERASE; N ACETYLGALACTOSAMINYLTRANSFERASE 1; UNCLASSIFIED DRUG; EGFR PROTEIN, HUMAN; POLYPEPTIDE N-ACETYLGALACTOSAMINYLTRANSFERASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CANCER CELL LINE; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OVERALL SURVIVAL; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; SIGNAL TRANSDUCTION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; DEFICIENCY; DOWN REGULATION; GENE SILENCING; GENETIC TRANSFECTION; GENETICS; GLYCOSYLATION; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHENOTYPE; PHYSIOLOGY; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; GENE KNOCKDOWN TECHNIQUES; GLYCOSYLATION; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICE, INBRED NOD; MICE, SCID; N-ACETYLGALACTOSAMINYLTRANSFERASES; PHENOTYPE; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TRANSFECTION; UP-REGULATION;

EID: 84925610442     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3117     Document Type: Article

References (36)

1. Chen PJ, Furuse J, Han KH, Hsu C, Lim HY, Moon H, Qin S, Ye SL, Yeoh EM, Yeo W. Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion. Liver international: official journal of the International Association for the Study of the Liver. 2010; 30:1427-1438.
2. Ferlay J SI, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer. 2013. [Internet] Available from: http://globocan.iarc.fr. (Accessed on 26/08/2014).
3. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. International journal of cancer Journal international du cancer. 2006; 119:1946-1952.
4. Chen CH, Su WW, Yang SS, Chang TT, Cheng KS, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Lu SN. Long-term trends and geographic variations in the survival of patients with hepatocellular carcinoma: analysis of 11, 312 patients in Taiwan. Journal of gastroenterology and hepatology. 2006; 21:1561-1566.
5. Yuen MF, Hou JL, Chutaputti A. Hepatocellular carcinoma in the Asia pacific region. Journal of gastroenterology and hepatology. 2009; 24:346-353.
6. Buckley AF, Burgart LJ, Sahai V, Kakar S. Epidermal growth factor receptor expression and gene copy number in conventional hepatocellular carcinoma. American journal of clinical pathology. 2008; 129:245-251.
7. Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA, Tabak LA. Control of mucin-type O-glycosylation: a classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 2012; 22:736-756.
8. Gerken TA, Raman J, Fritz TA, Jamison O. Identification of common and unique peptide substrate preferences for the UDP-GalNAc:polypeptide alpha-N-acetylgalactosaminyltransferases T1 and T2 derived from oriented random peptide substrates. The Journal of biological chemistry. 2006; 281:32403-32416.
9. Ten Hagen KG, Tran DT, Gerken TA, Stein DS, Zhang Z. Functional characterization and expression analysis of members of the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase family from Drosophila melanogaster. The Journal of biological chemistry. 2003; 278:35039-35048.
10. Brockhausen I. Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO reports. 2006; 7:599-604.
11. Hua D, Shen L, Xu L, Jiang Z, Zhou Y, Yue A, Zou S, Cheng Z, Wu S. Polypeptide N-acetylgalactosaminyltransferase 2 regulates cellular metastasis-associated behavior in gastric cancer. International journal of molecular medicine. 2012; 30:1267-1274.
12. Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, Huang HC, Huang MC. Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer research. 2011; 71:7270-7279.
13. Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, Matsumoto T, Sasaguri Y. Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. British journal of cancer. 2013; 109:472-481.
14. Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A, Bachvarov D. Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation. Oncotarget. 2014; 5:544-560.
15. Wang R, Yu C, Zhao D, Wu M, Yang Z. The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Oncology reports. 2013; 30:667-676.
16. Peng RQ, Wan HY, Li HF, Liu M, Li X, Tang H. MicroRNA-214 suppresses growth and invasiveness of cervical cancer cells by targeting UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylga lactosaminyltransferase 7. The Journal of biological chemistry. 2012; 287:14301-14309.
17. Gaziel-Sovran A, Segura MF, Di Micco R, Collins MK, Hanniford D, Vega-Saenz de Miera E, Rakus JF, Dankert JF, Shang S, Kerbel RS, Bhardwaj N, Shao Y, Darvishian F, Zavadil J, Erlebacher A, Mahal LK, et al. miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. Cancer cell. 2011; 20:104-118.
18. Xie Q, Su Y, Dykema K, Johnson J, Koeman J, De Giorgi V, Huang A, Schlegel R, Essenburg C, Kang L, Iwaya K, Seki S, Khoo SK, Zhang B, Buonaguro F, Marincola FM, et al. Overexpression of HGF Promotes HBV-Induced Hepatocellular Carcinoma Progression and Is an Effective Indicator for Met-Targeting Therapy. Genes & cancer. 2013; 4:247-260.
19. Sandhu DS, Baichoo E, Roberts LR. Fibroblast growth factor signaling in liver carcinogenesis. Hepatology (Baltimore, Md). 2014; 59:1166-1173.
20. Yang H, Fang F, Chang R, Yang L. MicroRNA-140-5p suppresses tumor growth and metastasis by targeting transforming growth factor beta receptor 1 and fibroblast growth factor 9 in hepatocellular carcinoma. Hepatology (Baltimore, Md). 2013; 58:205-217.
21. Lau CK, Yang ZF, Ho DW, Ng MN, Yeoh GC, Poon RT, Fan ST. An Akt/hypoxia-inducible factor-1alpha/platelet-derived growth factor-BB autocrine loop mediates hypoxia-induced chemoresistance in liver cancer cells and tumorigenic hepatic progenitor cells. Clinical cancer research: an official journal of the American Association for Cancer Research. 2009; 15:3462-3471.
22. Peng S, Wang Y, Peng H, Chen D, Shen S, Peng B, Chen M, Lencioni R, Kuang M. Autocrine vascular endothelial growth factor signaling promotes cell proliferation and modulates sorafenib treatment efficacy in hepatocellular carcinoma. Hepatology (Baltimore, Md). 2014; 60:1264-1277.
23. Fuchs BC, Hoshida Y, Fujii T, Wei L, Yamada S, Lauwers GY, McGinn CM, DePeralta DK, Chen X, Kuroda T, Lanuti M, Schmitt AD, Gupta S, Crenshaw A, Onofrio R, Taylor B, et al. Epidermal growth factor receptor inhibition attenuates liver fibrosis and development of hepatocellular carcinoma. Hepatology (Baltimore, Md). 2014; 59:1577-1590.
24. Tonjes RR, Lohler J, O'Sullivan JF, Kay GF, Schmidt GH, Dalemans W, Pavirani A, Paul D. Autocrine mitogen IgEGF cooperates with c-myc or with the Hcs locus during hepatocarcinogenesis in transgenic mice. Oncogene. 1995; 10:765-768.
25. Huang P, Xu X, Wang L, Zhu B, Wang X, Xia J. The role of EGF-EGFR signalling pathway in hepatocellular carcinoma inflammatory microenvironment. Journal of cellular and molecular medicine. 2014; 18:218-230.
26. Le Roy C, Wrana JL. Clathrin-and non-clathrin-mediated endocytic regulation of cell signalling. Nature reviews Molecular cell biology. 2005; 6:112-126.
27. Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nature medicine. 2013; 19:1389-1400.
28. Desai MD, Saroya BS, Lockhart AC. Investigational therapies targeting the ErbB (EGFR, HER2, HER3, HER4) ErbB family in GI cancers. Expert opinion on investigational drugs. 2013; 22:341-356.
29. von Zastrow M, Sorkin A. Signaling on the endocytic pathway. Current opinion in cell biology. 2007; 19:436-445.
30. Murphy JE, Padilla BE, Hasdemir B, Cottrell GS, Bunnett NW. Endosomes: a legitimate platform for the signaling train. Proceedings of the National Academy of Sciences of the United States of America. 2009; 106:17615-17622.
31. Miaczynska M, Pelkmans L, Zerial M. Not just a sink: endosomes in control of signal transduction. Current opinion in cell biology. 2004; 16:400-406.
32. Odintsova E, Voortman J, Gilbert E, Berditchevski F. Tetraspanin CD82 regulates compartmentalisation and ligand-induced dimerization of EGFR. Journal of cell science. 2003; 116:4557-4566.
33. Sousa LP, Lax I, Shen H, Ferguson SM, De Camilli P, Schlessinger J. Suppression of EGFR endocytosis by dynamin depletion reveals that EGFR signaling occurs primarily at the plasma membrane. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:4419-4424.
34. Holleboom AG, Karlsson H, Lin RS, Beres TM, Sierts JA, Herman DS, Stroes ES, Aerts JM, Kastelein JJ, Motazacker MM, Dallinga-Thie GM, Levels JH, Zwinderman AH, Seidman JG, Seidman CE, Ljunggren S, et al. Heterozygosity for a loss-of-function mutation in GALNT2 improves plasma triglyceride clearance in man. Cell metabolism. 2011; 14:811-818.
35. Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network-based method for gene-set enrichment visualization and interpretation. PloS one. 2010; 5:e13984.
36. Cline MS, Smoot M, Cerami E, Kuchinsky A, Landys N, Workman C, Christmas R, Avila-Campilo I, Creech M, Gross B, Hanspers K, Isserlin R, Kelley R, Killcoyne S, Lotia S, Maere S, et al. Integration of biological networks and gene expression data using Cytoscape. Nature protocols. 2007; 2:2366-2382.